Robert F. Kennedy Jr. begins his podcast. The Secretary of Health and Human Services (HHS) announced the show on social media, saying he framed the podcast as a response to a public health issue that led “many of us…to conclude that (the government) is, in fact, lying to us.”
The podcast gave RFK Jr., a longtime critic of vaccines and the pharmaceutical industry, a new channel to get his thoughts across. RFK Jr.’s rise to the top of HHS creates an already difficult environment for the biopharmaceutical industry, particularly vaccine makers who are struggling with how to get their message across amid growing opposition to their products.
In his post, RFK Jr. said the podcast will feature “fearless conversations with critical thinkers including independent physicians, respected scientists, and leaders in medical innovation and research.” The Health Secretary added: “We will lift taboos and expose hypocrisy, conflict and corruption.”
In RFK Jr.’s view, America needs to “confront the lies that have made us mentally, morally and physically ill” in order to become a healthy nation. HHS leaders said that after decades of being told to trust the system, Americans are seeing their children getting sicker, chronic diseases exploding, and the answers they’ve been given not working.
As of publication, an HHS spokesperson had not yet responded to a request for more information. However, RFK Jr.’s track record and comments in the video announcing the podcast suggest that the show could further increase the challenges facing biopharmaceutical communications teams.
Sanofi’s then-CEO Paul Hudson said at the JPMorgan Healthcare Conference in January that the company “must address uncertainty around vaccination rates in the short term based on misinformation, Facebook posts and comments from senior leadership.” Mr Hudson added that Sanofi’s strategy was to give patients and parents the best possible advice.
But it’s unclear whether patients and parents will listen. Michael Pass, AbbVie’s head of value and access, said at a Gabelli Fund event last year that the pharmaceutical industry’s image and trust issues mean it’s not necessarily the best messenger for the messages drug companies want to convey. Paz said sometimes it’s better if the message comes from someone else.
